Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-08-15

Clinical Trial Update: Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50 [Phase 3]

View source ↗

Summary

Phase 3 trial investigating ivermectin to prevent COVID-19–related hospitalization in adults over 50 was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IVERMECTIN (Ivermectin)

Snippet

Sponsor: Insud Pharma | Conditions: COVID-19, SARS-CoV-2 | Phase 3 | Status: TERMINATED